Agenus vs Valneva
AGEN and VALN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGEN and VALN compare
Agenus grew revenue faster over the last twelve months (25.4% versus −27.2% for Valneva).
Agenus scores higher on the StockData Score (3 against 1 for Valneva), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGEN | VALN |
|---|---|---|
| Size and price | ||
| Market cap | $309M | – |
| Share price | $6.87 | $5.66 |
| Change, 1 year | 60.9% | −38.4% |
| Change, 5 years | −90.2% | −88.4% |
| Beta (5Y) | 2.03 | 1.67 |
| Employees | 81 | 140 |
| StockData Score | ||
| Total score | 3 (better) | 1 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 (better) | 0 |
| Performance score | 0 | 0 |
| Health score | 0 | 1 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 2.3× | – |
| EV/EBITDA | 4.5× | – |
| FCF yield | −33.6% | – |
| Growth | ||
| Revenue growth (TTM) | 25.4% (better) | −27.2% |
| Revenue growth, 5Y average | 5.3% | 9.6% (better) |
| Profitability | ||
| Gross margin | 100% (better) | 16.4% |
| Operating margin | 38.9% (better) | −80.5% |
| FCF margin | −77.5% | −40.6% (better) |
| Financial health | ||
| Net debt / EBITDA | −1.05 | – |
| Interest coverage | 0.9× (better) | −2.8× |
| Current ratio | 0.73 | 2.16 (better) |
| Altman Z-score | −10.71 | – |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | – |
| Ownership | ||
| Held by institutions | 31.7% | 2.2% |
| Held by insiders | 6.6% | 11.0% |
| Short interest, % of float | 18.1% | – |
Go deeper
- AGEN stock overview
- AGEN income statement
- AGEN valuation and score
- VALN stock overview
- VALN income statement
- VALN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.